These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 15174468

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Drug interactions. Kaletra and ezetimibe.
    TreatmentUpdate; 2006; 18(3):8. PubMed ID: 17209242
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract] [Full Text] [Related]

  • 26. [Atazanavir-induced nephrolithiasis].
    Valencia ME, Moreno V.
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
    [No Abstract] [Full Text] [Related]

  • 27. CASTLE data show no gender differences.
    AIDS Patient Care STDS; 2008 Sep; 22(9):762. PubMed ID: 18802980
    [No Abstract] [Full Text] [Related]

  • 28. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009 Sep; 21(3):3-4. PubMed ID: 19623725
    [No Abstract] [Full Text] [Related]

  • 29. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
    MMW Fortschr Med; 2003 Dec 11; 145(50):60-1. PubMed ID: 14963980
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004 Dec 11; 16(3):9-10. PubMed ID: 17219610
    [No Abstract] [Full Text] [Related]

  • 32. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
    Bongiovanni M, Chiesa E, Monforte Ad, Bini T.
    Dermatol Online J; 2003 Dec 11; 9(5):28. PubMed ID: 14996401
    [No Abstract] [Full Text] [Related]

  • 33. Kaletra versus nelfinavir.
    TreatmentUpdate; 2001 Dec 11; 12(12):8-10. PubMed ID: 11570097
    [No Abstract] [Full Text] [Related]

  • 34. [Efficacy of atazanavir in rescue therapy].
    Portilla J, Boix V, Merino E, Reus S.
    Enferm Infecc Microbiol Clin; 2008 Dec 11; 26 Suppl 17():22-7. PubMed ID: 20116613
    [Abstract] [Full Text] [Related]

  • 35. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr 25; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract] [Full Text] [Related]

  • 36. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.
    Pharmacotherapy; 2008 Mar 25; 28(3):323-30. PubMed ID: 18294112
    [Abstract] [Full Text] [Related]

  • 37. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
    Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, Wu Y, Arikan D, Farajallah A, Bertz R.
    J Antimicrob Chemother; 2011 Sep 25; 66(9):2075-82. PubMed ID: 21712242
    [Abstract] [Full Text] [Related]

  • 38. [Adverse effects of atazanavir].
    Palacios R, González M, Ruiz J, Santos J.
    Enferm Infecc Microbiol Clin; 2008 Dec 25; 26 Suppl 17():41-4. PubMed ID: 20116616
    [Abstract] [Full Text] [Related]

  • 39. [Clinical utility of atazanavir].
    Ribera Pascuet E, Curran A.
    Enferm Infecc Microbiol Clin; 2008 Dec 25; 26 Suppl 17():55-67. PubMed ID: 20116619
    [Abstract] [Full Text] [Related]

  • 40. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S, Bellón JM, Muñoz-Fernández MA, Spanish Group of HIV Infection.
    J Antimicrob Chemother; 2006 Mar 25; 57(3):579-82. PubMed ID: 16446377
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.